Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation

References

• Bunch TJ, Gersh BJ. Rhythm control strategies and the role of antiarrhythmic drugs in the management of atrial fibrillation: focus on clinical outcomes. J General Intern Med. 2011;26(5):531–537.
   PubMed Web of Science ®Google Scholar
• Bajpai A, Savelieva I, Camm A. Epidemiology and economic burden of atrial fibrillation. US Cardiol. 2007;4(1):14–17.
   Google Scholar
• Kannel W, Benjamin E. Final draft status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008;92(1):17–ix.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(7):2N–9N.
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary. Circulation. 2006;114(7):700–752.
   Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
   PubMed Web of Science ®Google Scholar
• Hart R, Pearce L, Aguilar M. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• Warfarin 0.5 mg tablets. Electronic medicines compendium. 2017. https://www.medicines.org.uk/emc/medicine/27651. [cited 2018 Dec 10]
   Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ V, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Briere J, Bowrin K, Coleman C, et al. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2019;19(1):27–36.
   PubMed Web of Science ®Google Scholar
• Coleman C, Briere J-B, Fauchier L, et al. Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. J Market Access HealthPolicy. 2019;7(1):1574541.
   PubMedGoogle Scholar
• Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fi brillation among general practices in England. Heart. 2013;99(16):1166–1172.
   PubMed Web of Science ®Google Scholar
• Mendes D, Alves C, Batel-Marques F. Number needed to treat (NNT) in clinical literature: an appraisal. BMC Med. 2017;15(1):112.
   PubMedGoogle Scholar
• Suissa S. The number needed to treat: 25 years of trials and tribulations in clinical research. Rambam Maimonides Med J. 2015;6(3):e0033.
   Web of Science ®Google Scholar
• Cates CJ. Simpson’s paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol. 2002;2:1.
   PubMedGoogle Scholar
• Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728–1733.
   PubMed Web of Science ®Google Scholar
• Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(December):1492–1495.
   PubMedGoogle Scholar
• Lubsen J, Hoes A, Grobbee D. Implications of trial results: the potentially misleading notions of number needed to treat and average duration of life gained. Lancet. 2000;356(9243):1757–1759.
   PubMed Web of Science ®Google Scholar
• Schmitz S, Adams R, Walsh C. Incorporating data from various trial designs into a mixed treatment comparison model. Stat Med. 2013;32(17):2935–2949.
   PubMed Web of Science ®Google Scholar
• Moore RA, Gavaghan DJ, Edwards JE, et al. Pooling data for number needed to treat: no problems for apples. BMC Med Res Methodol. 2002;2:2.
   PubMedGoogle Scholar
• McAlister FA. The “number needed to treat” turns 20—and continues to be used and misused. CMAJ. 2008;179(6):549–553.
   PubMed Web of Science ®Google Scholar
• Altman D, Schulz K, Moher D, et al. The revised consort statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8):663–694.
   PubMed Web of Science ®Google Scholar
• Stang A, Poole C, Bender R. Common problems related to the use of number needed to treat. J Clin Epidemiol. 2010;63(8):820–825.
   PubMed Web of Science ®Google Scholar
• Bender R. Using and interpreting adjusted NNT measures in biomedical research. Open Dent J. 2010;4:72–76.
   PubMedGoogle Scholar
• Mayne TJ, Whalen E, Vu A. Annualized was found better than absolute risk reduction in the calculation of number needed to treat in chronic conditions. J Clin Epidemiol. 2006;59(3):217–223.
   PubMed Web of Science ®Google Scholar
• Ke C, Jiang Q. Benefit–risk assessment using number needed to treat and number needed to harm for time-to-event endpoints. Stat Biopharm Res. 2016;8(4):379–385.
   Web of Science ®Google Scholar
• Kannus P. Structure of the tendon connective tissue. Scand J Med Sci Sports. 2000;10(6):312–320.
   PubMed Web of Science ®Google Scholar
• Altman DG, Deeks JJ. Meta-analysis, Simpson’s paradox, and the number needed to treat. BMC Med Res Methodol. 2002;2(1):3.
   PubMedGoogle Scholar
• Cates DH, Eggert C, Yang JL, et al. Comparison of effluents from TCF and ECF bleaching of kraft pulps. Tappi J. 1995;78(12):93–98.
   Web of Science ®Google Scholar
• Furukawa T, Guyatt G, Griffith L. Can we individualize the “number needed to treat”? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol. 2002;31(1):72–76.
   PubMed Web of Science ®Google Scholar
• Proietti M, Romanazzi I, Romiti GF, et al. Real-world use of apixaban for stroke prevention in atrial fibrillation. Stroke. 2018;49(1):98–106.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Farmer C, Luo X, et al. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. Curr Med Res Opin. 2018;34(3):487–498.
   PubMed Web of Science ®Google Scholar